Leucine-Rich Repeats and Immunoglobulin-Like Domains 1 (Lrig1) (C-Term) antibody

Details for Product No. ABIN125884
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Synonyms LIG-1, LIG1, D6Bwg0781e, Img
(17), (15), (12), (1), (1), (1), (1), (1)
Human, Mouse (Murine)
(29), (20), (13)
(33), (1), (1)
(3), (3), (3), (2), (2), (2), (1), (1), (1), (1), (1), (1), (1), (1)
Western Blotting (WB)
(25), (12), (10), (6), (3), (1), (1), (1), (1), (1)
Pubmed 5 references available
Quantity 100 μg
Shipping to United States (Change)
Availability Will be delivered in 5 to 6 Business Days
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Catalog No. ABIN125884
627.99 $
Plus shipping costs $45.00

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen KLH-conjugated synthetic peptide, the peptide corresponds to part of the cytoplasmic tail (C-terminal part) of the protein
Isotype IgG
Predicted Reactivity Human
Characteristics Expected / apparent Molecular Weight of the Antigene: 143 kDa
Purification affinity purified
Alternative Name LRIG1
Background LRIG1 protein Q96JA1 is coded by a gene on a chromosome band 3p14.3, this region is known to be deleted in various human cancers. LRIG1 is considered to be a a tumour suppressor gene in humans. LRIG1 is an integral cell-surface membrane protein that is expressed by specific cells in various human tissues and that its 143-kDa form might be cleaved into 111-kDa and 32-kDa fragments. The LRIG1 protein may inhibit the growth of tumors of glial cells and the down-regulation of the LRIG1 gene may be involved in the development and progression of the tumor.
Molecular Weight 143 kDa
UniProt Q96JA1
Research Area Cancer
Application Notes Recommended Dilution: 1 µg/mL (WB), use at an assay dependent dilution (IHC) MW.

immunoblotting demonstrated LRIG1 protein in tissue lysates from normal human prostate, mammary epithelial cells, ileum, stomach, lung, and cerebral cortex

Restrictions For Research Use only
Format Lyophilized
Reconstitution For reconstitution add 90,9 µL of sterile water.
Buffer PBS pH 7.4 BSA 1 mg/mL
Handling Advice Please, remember to spin tubes briefly prior to opening them to avoid any losses that might occur from lyophilized material adhering to the cap or sides of the tubes.
Once reconstituted make aliquots to avoid repreated freeze-thaw cycles.
Storage -20 °C
Supplier Images
anti-Leucine-Rich Repeats and Immunoglobulin-Like Domains 1 (Lrig1) (C-Term) antibody Western Blot has been done using: The COS-7 cells transfected with expression vectors encoding LRIG1 (line 1) or LRIG2 (Line 2) and ZR-75, a breast carcinoma cell line (Line 3). Loading: 0.5 microgram of COS-7 lysates and 10 microgram of ZR-75 lysate.
Product cited in: Häggström, Cipriano, Forshell et al.: "Potential upstream regulators of cannabinoid receptor 1 signaling in prostate cancer: A Bayesian network analysis of data from a tissue microarray." in: The Prostate, Vol. 74, Issue 11, pp. 1107-17, 2014 (PubMed).

Background publications Ledda, Bieraugel, Fard et al.: "Lrig1 is an endogenous inhibitor of Ret receptor tyrosine kinase activation, downstream signaling, and biological responses to GDNF." in: The Journal of neuroscience : the official journal of the Society for Neuroscience, Vol. 28, Issue 1, pp. 39-49, 2008 (PubMed).

General Thomasson, Wang, Hammarsten et al.: "LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer." in: International journal of cancer. Journal international du cancer, Vol. 128, Issue 12, pp. 2843-52, 2011 (PubMed).

Miller, Shattuck, Ingalla et al.: "Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer." in: Cancer research, Vol. 68, Issue 20, pp. 8286-94, 2008 (PubMed).

Stutz, Shattuck, Laederich et al.: "LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII." in: Oncogene, Vol. 27, Issue 43, pp. 5741-52, 2008 (PubMed).

Validation Images
Did you look for something else?
back to top